Skip to main content
. 2007 Dec;2(4):551–559.

Table 1.

Clinical success rates in studies evaluating azithromycin against comparators in the treatment of lower respiratory tract infections

First author, year Setting Azithromycin dosing scheme Comparator/s dosing scheme No. of treated patients Clinical success rate
Bohte 1995 CAP 500 mg once daily, 3 days Benzylpenicillin i.v. 35 azitromycin vs Azithromycin 83% vs
Erythromycin 29 benzylpenicillin Benzylpenicillin 66%
19 azithromycin vs Azithromycin 79% vs
21 erythromycin Erythromycin 76%
O’Doherty 1998 CAP 500 mg once daily, 3 days Clarithromycin 250 mg twice daily, 10 days 101 azithromycin Azithromycin 94%
102 clarithromycin Clarithromycin 95%
Bradbury 1993 LRTI 500 mg once daily, 3 days Clarithromycin 250 mg twice daily, 10 days 252 azithromycin Azithromycin 94%
258 clarithromycin Clarithromycin 97%
Hoepelman 1997 LRTI 500 mg once daily, 3 days Amoxi/clav acid 625 mg 3 times daily, 10 days 62 azithromycin Azithromycin 95%
61 amoxi/clav acid Amoxi/clav 90%
DeAbate 2000 AECB 500 mg day 1, 250 mg days 2–5 Moxifloxacin 400 mg once daily, 5 days 243 azithromycin Azithromycin 92%
221 moxifloxacin Moxifloxacin 90%
Amsden 2003 AECB 500 mg day 1, 250 mg days 2–5 Levofloxacin 500 mg once daily, 7 days 118 azithromycin Azithromycin 89%
117 levofloxacin Levofloxacin 92%
Castaldo 2003 AECB 500 mg day 1, 250 mg days 2–5 Dirithromycin 500 mg once daily, 5 days 46 azithromycin Azithromycin 86.5%
40 dirithromycin Dirithromycin 95.5%

Abbreviations: CAP, community-acquired pneumonia; LRTI, lower respiratory tract infections; AECB, acute exacerbations of chronic bronchitis; Amoxi/clav, amoxicillin/clavulanic acid.